MedTrace Logo

Effects of Buspar on Depressive Symptom Improvement and Neuroprotection in Patients With Anxiety Disorder

NCT01546896 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2015-05-20

No results posted yet for this study

Summary

This research aims to investigate the efficacy and safety of buspirone in treating generalized anxiety disorder with depressive symptoms and to evaluate its neuroprotective effects using magnetic resonance imaging.

Conditions

  • Anxiety Disorder

Interventions

DRUG

buspirone+alprazolam

day 1\~7: buspirone 10mg/d + alprazolam 0.5mg / day 8\~28: buspirone 20mg/d + alprazolam 0.5mg / day 29\~56: buspirone 20\~30mg/d + alprazolam 0.5mg

DRUG

alprazolam

0.5mg/d

Sponsors & Collaborators

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • In Kyoon Lyoo, MD, PhD, MMS · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2014-02-28
Completion
2014-02-28

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01546896 on ClinicalTrials.gov